Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.

Bomback, Andrew S.

Mineralocorticoid receptor antagonists (MRAs) that block aldosterone's effects on both epithelial and non-epithelial receptors have become a mainstay of therapy for chronic heart failure. Given that cardiovascular events remain the leading cause of death for patients with end-stage renal disease (ESRD), the question of whether these MRAs can be employed in dialysis patients arises. This review summarizes the rationale for blocking aldosterone in patients with chronic and end-stage kidney disease and surveys the data on both the efficacy and safety of using MRAs in the ESRD population. A small but growing body of literature suggests that use of MRAs by ESRD patients is associated with lower blood pressure, reduced left ventricular (LV) mass, and improved LV ejection fraction. Recently, a large randomized trial found an overall 3-year mortality rate of 6.4% in ESRD patients on spironolactone 25 mg daily vs. 19.7% in ESRD patients on no MRA therapy (p = 0.002), without a significantly increased risk of hyperkalemia.

MINERALOCORTICOID receptors; HORMONE antagonists; CHRONIC kidney failure; DRUG efficacy; MEDICATION safety; PATIENTS

Blood Purification, 2016, Vol 41, Issue 1-3, p166

0253-5068

Academic Journal

10.1159/000441262